Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

Veracyte, Inc. , a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic Classifier for use in patients whose prostate cancer has spread beyond ...

"At Castle Biosciences, our commitment to advancing care for melanoma patients helps drive our continuous innovation," said Rebecca Critchley-Thorne, Ph.D., vice president, research and development, ...

It is the only gene expression test to achieve “Level I” evidence status and inclusion in the risk-stratification table in the most recent NCCN® Guidelines* for prostate cancer. More ...

Discover NovoCure's Q1 2025 earnings insights, including Optune Lua's NSCLC progress, global market growth, and strong revenue performance.

Overall, the one-time LDCT diagnostic performance in the non-risk-based screening population had a sensitivity of 96.6%, a ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

Taiwan’s health authority on Thursday said it has plans to expand existing National Health Insurance (NHI) coverage to ...